Les publications

Page en cours de mise à jour... Retrouvez ici les publications des équipes de recherche du CGO

413 publications
Année de publication :
Réseaux :

Skin inflammatory response and efficacy of anti-epidermal growth factor receptor therapy in metastatic colorectal cancer (CUTACETUX).

Anti-epidermal growth factor receptor (EGFR) monoclonal antibody is a standard treatment of metastatic colorectal cancer (mCRC) and its most common adverse effect is a papulopustular acneiform rash.

  • Ref: Oncoimmunology. 2020 Nov 29;9(1):1848058.
  • Année de publication : 2020
  • Auteurs : Tougeron D, Emambux S, Favot L, Lecomte T, Wierzbicka-Hainaut E, Samimi M, Frouin E, Azzopardi N, Chevrier J, Serres L, Godet J, Levillain P, Paintaud G, Ferru A, Rouleau L, Delwail A, Silvain C, Tasu JP, Morel F, Ragot S, Lecron JC.
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication

Panel gene profiling of small bowel adenocarcinoma: Results from the NADEGE prospective cohort.

Small bowel adenocarcinoma (SBA) is a rare tumour. Large genomic analyses with prognostic assessments are lacking. The NADEGE cohort has enrolled 347 patients with all stage SBA from 2009 to 2012. Next-generation sequencing investigates the presence of 740 hotspot somatic mutations in a panel of 46 genes involved in carcinogenesis.

  • Ref: Int J Cancer. 2020 Nov 13.
  • Année de publication : 2020
  • Auteurs : Aparicio T, Svrcek M, Henriques J, Afchain P, Lièvre A, Tougeron D, Gagniere J, Terrebonne E, Piessen G, Legoux JL, Lecaille C, Pocard M, Gornet JM, Zaanan A, Lavau-Denes S, Lecomte T, Deutsch D, Vernerey D, Puig PL.
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication

PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line…

Gastric or gastro-oesophageal junction (GEJ) adenocarcinomas present poor overall survival (OS). First-line chemotherapy regimen for patients with HER2-negative tumours is based on a doublet or triplet of fluoropyrimidine plus platinum salt ± taxane.

  • Ref: Dig Liver Dis. 2020 Dec 21:S1590-8658(20)31057-4.
  • Année de publication : 2020
  • Auteurs : Evrard C, Louvet C, Hajbi FE, Fiore FD, Malicot KL, Aparicio T, Bouché O, Laurent-Puig P, Bibeau F, Lecomte T, Lièvre A, Guimbaud R, Kim S, Zaanan A, Sokol H, Chibaudel B, Desrame J, Pierre S, Gonzalez D, Lepage C, Tougeron D.
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication

Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A…

FOLFIRI (irinotecan, 5-fluorouracil, and leucovorin) + aflibercept improves median overall survival (OS) and progression-free survival (PFS) in patients with previously treated metastatic colorectal cancer (mCRC).

  • Ref: Clin Colorectal Cancer. 2020 Dec;19(4):285-290.
  • Année de publication : 2020
  • Auteurs : Lapeyre-Prost A, Pernot S, Sigrand J, Le Malicot K, Mary F, Aparicio T, Dahan L, Caroli-Bosc FX, Lecomte T, Doat S, Marthey L, Desrame J, Lepage C, Taieb J.
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication

Neospora caninum: a new class of biopharmaceuticals in the therapeutic arsenal against cancer.

Microorganisms that can be used for their lytic activity against tumor cells as well as inducing or reactivating antitumor immune responses are a relevant part of the available immunotherapy strategies. Viruses, bacteria and even protozoa have been largely explored with success as effective human antitumor agents.

  • Ref: J Immunother Cancer. 2020 Nov;8(2):e001242.
  • Année de publication : 2020
  • Auteurs : Lantier L, Poupée-Beaugé A, di Tommaso A, Ducournau C, Epardaud M, Lakhrif Z, Germon S, Debierre-Grockiego F, Mévélec MN, Battistoni A, Coënon L, Deluce-Kakwata-Nkor N, Velge-Roussel F, Beauvillain C, Baranek T, Lee GS, Kervarrec T, Touzé A, Moiré N, Dimier-Poisson I.
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication

Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance.

T cell exclusion causes resistance to cancer immunotherapies via immune checkpoint blockade (ICB). Myeloid cells contribute to resistance by expressing signal regulatory protein-α (SIRPα), an inhibitory membrane receptor that interacts with ubiquitous receptor CD47 to control macrophage phagocytosis in the tumor microenvironment.

  • Ref: J Clin Invest. 2020 Nov 2;130(11):6109-6123.
  • Année de publication : 2020
  • Auteurs : Gauttier V, Pengam S, Durand J, Biteau K, Mary C, Morello A, Néel M, Porto G, Teppaz G, Thepenier V, Danger R, Vince N, Wilhelm E, Girault I, Abes R, Ruiz C, Trilleaud C, Duplouye P, Miyasaka M, Labarrière N, Laplaud D, Le Bas-Bernardet S, Blanquart C, Catros V, Gouraud PA, Archambeaud I, Aublé H, Metairie S, Mosnier JF, Costantini D, Blancho G, Conchon S, Vanhove B, Poirier N.
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication

Recurrence Pattern of Cervical Cancer Based on the Platinum Sensitivity Concept: A Multi-Institutional Study from the…

The standard of care for patients with advanced cervical cancer (ACC) includes platinum-based chemotherapy. The concept of platinum sensitivity is a major prognostic factor for patients with ovarian cancer.

  • Ref: J Clin Med. 2020 Nov 12;9(11):3646.
  • Année de publication : 2020
  • Auteurs : de Foucher T, Hennebert C, Dabi Y, Ouldamer L, Lavoué V, Dion L, Canlorbe G, Bolze PA, Golfier F, Akladios C, Lecointre L, Kerbage Y, Collinet P, Bricou A, Carcopino X, Huchon C, Raimond E, Graesslin O, Owen C, Touboul C, Ballester M, Darai E, Bendifallah S.
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication

Accuracy of peritoneal carcinomatosis extent diagnosis by initial FDG PET CT in epithelial ovarian cancer: A…

Peritoneal carcinomatosis extent in ovarian cancer is difficult to evaluate by imaging techniques even though it determines the surgical complexity and survival. The aim of this study was to estimate the accuracy of 2-[18F]-fluoro-2-deoxy-d-glucose (FDG)-PET CT (Positron-emission tomography coupled with Computerised Tomography) performed before any treatment, in the diagnosis of the extent of peritoneal carcinomatosis.

  • Ref: J Gynecol Obstet Hum Reprod. 2020 Nov;49(9):101867.
  • Année de publication : 2020
  • Auteurs : Delvallée J, Rossard L, Bendifallah S, Touboul C, Collinet P, Bricou A, Huchon C, Lavoue V, Body G, Ouldamer L.
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication

Integrative molecular profiling of autoreactive CD4 T cells in autoimmune hepatitis.

In most autoimmune disorders, crosstalk of B cells and CD4 T cells results in the accumulation of autoantibodies. In autoimmune hepatitis (AIH), the presence of anti-soluble liver antigen (SLA) autoantibodies is associated with reduced overall survival, but the associated autoreactive CD4 T cells have not yet been characterised.

  • Ref: J Hepatol. 2020 Dec;73(6):1379-1390.
  • Année de publication : 2020
  • Auteurs : Renand A, Cervera-Marzal I, Gil L, Dong C, Garcia A, Kervagoret E, Aublé H, Habes S, Chevalier C, Vavasseur F, Clémenceau B, Cardon A, Judor JP, Mosnier JF, Tanné F, Laplaud DA, Brouard S, Gournay J, Milpied P, Conchon S.
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication

DNA hydroxymethylation is associated with disease severity and persists at enhancers of oncogenic regions in multiple…

Multiple myeloma (MM) is a heterogeneous plasma cell malignancy that remains challenging to cure. Global hypomethylation correlates with an aggressive phenotype of the disease, while hypermethylation is observed at particular regions of myeloma such as B cell-specific enhancers.

  • Ref: Clin Epigenetics. 2020 Nov 2;12(1):163.
  • Année de publication : 2020
  • Auteurs : Alberge JB, Magrangeas F, Wagner M, Denié S, Guérin-Charbonnel C, Campion L, Attal M, Avet-Loiseau H, Carell T, Moreau P, Minvielle S, Sérandour AA.
  • Réseaux : Réseaux: « Niches et Epigénétique des Tumeurs »
Lire la publication